The polled odds ratio (OR) for overall response rate (ORR) was 1.64 (Figure 4; 95% CI 1.19–2.26, P < 0.05), which suggested a higher clinical response rate for anti-PD-1/PD-L1 antibodies than for docetaxel in advanced NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.